Valuation Metrics and Recent Changes
As of 20 March 2026, Valiant Organics trades at ₹260.50, up 9.57% from the previous close of ₹237.75. The stock’s 52-week range spans from ₹195.20 to ₹508.30, indicating significant volatility over the past year. The company’s price-to-earnings (P/E) ratio stands at 40.19, a figure that, while high, is considered attractive relative to its historical valuation and peer group. The price-to-book value (P/BV) ratio is 0.99, suggesting the stock is trading close to its book value, a factor that supports the recent upgrade in valuation attractiveness.
Other valuation multiples include an enterprise value to EBIT (EV/EBIT) of 22.14 and an EV to EBITDA of 11.72, which are moderate within the specialty chemicals industry context. The EV to capital employed and EV to sales ratios both hover around 0.99 and 1.32 respectively, indicating a balanced valuation relative to the company’s asset base and revenue generation.
Profitability and Efficiency Indicators
Despite the improved valuation grade, Valiant Organics’ profitability metrics remain subdued. The return on capital employed (ROCE) is 4.56%, and return on equity (ROE) is 3.18%, both figures that fall short of industry averages and peer benchmarks. These low returns highlight challenges in operational efficiency and capital utilisation, which likely contributed to the downgrade in the Mojo Grade from Hold to Sell despite the more attractive valuation.
Peer Comparison: Valuation and Multiples
When compared with peers in the specialty chemicals sector, Valiant Organics’ valuation multiples present a mixed picture. For instance, Bliss GVS Pharma trades at a P/E of 19.97 with a fair valuation grade, while Shukra Pharma is deemed very expensive with a P/E of 59.03. Kwality Pharma and Jagsonpal Pharma also fall into the expensive category with P/E ratios of 28.42 and 28.68 respectively.
Valiant Organics’ P/E of 40.19 places it in the attractive valuation bracket, suggesting that the market may be pricing in growth potential or undervaluing certain aspects of the business. Its PEG ratio of 0.21 is notably low compared to peers such as Bliss GVS Pharma (0.83) and Jagsonpal Pharma (1.54), indicating that the stock’s price growth relative to earnings growth is favourable. However, the company’s EV/EBITDA multiple of 11.72 is lower than some peers but higher than others, reflecting a moderate valuation stance.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Stock Performance Relative to Sensex
Valiant Organics has delivered mixed returns over various time horizons compared to the benchmark Sensex index. Over the past week, the stock surged 22.53%, significantly outperforming the Sensex’s decline of 2.40%. Over one month, the stock gained 7.31%, while the Sensex fell 10.05%. Year-to-date, however, Valiant Organics has declined 5.01%, though this is still better than the Sensex’s 12.92% drop.
Longer-term performance paints a more challenging picture. Over three years, the stock has lost 32.42%, whereas the Sensex gained 27.97%. The five-year return is even more stark, with Valiant Organics down 79.51% compared to the Sensex’s 48.84% rise. These figures underscore the stock’s volatility and the importance of valuation adjustments in assessing its investment appeal.
Market Capitalisation and Risk Profile
Valiant Organics is classified as a micro-cap stock, which inherently carries higher risk due to lower liquidity and greater price swings. The company’s Mojo Score of 42.0 and a recent downgrade to a Sell grade reflect concerns about its financial health and growth prospects despite the improved valuation parameters. Investors should weigh these risks carefully against the potential for price appreciation suggested by the attractive P/E and PEG ratios.
Outlook and Investment Considerations
The shift in valuation grade from very attractive to attractive indicates a recalibration of market expectations for Valiant Organics. While the stock’s multiples suggest it is reasonably priced relative to book value and earnings growth, the company’s modest profitability and underwhelming returns on capital temper enthusiasm. The downgrade in Mojo Grade signals caution, highlighting that valuation alone does not guarantee investment success.
Investors should consider the broader industry context, where several peers trade at higher multiples with varying growth and risk profiles. The specialty chemicals sector remains competitive, and companies with stronger operational metrics and growth visibility may offer better risk-adjusted returns.
Valiant Organics Ltd or something better? Our SwitchER feature analyzes this micro-cap Specialty Chemicals stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion
Valiant Organics Ltd’s recent valuation upgrade to attractive reflects a more favourable pricing environment, supported by a P/E of 40.19 and a PEG ratio of 0.21, which are competitive within its peer group. However, the company’s low ROCE and ROE, combined with a downgrade in its overall Mojo Grade to Sell, suggest that investors should approach with caution. The stock’s mixed performance relative to the Sensex and its micro-cap status add layers of risk that must be carefully considered.
For investors seeking exposure to the specialty chemicals sector, it is prudent to balance valuation attractiveness with operational strength and market positioning. Valiant Organics offers an intriguing valuation case but requires close monitoring of its financial health and sector dynamics before committing capital.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
